19
| 3 | 2011
Klinisk Biokemi i Norden
Referenser:
1.
Kuriyama M, Wang MC, Papsidero LD, Kil-
lian CS, Shimano T, Valenzuela L, Nishiura T,
Murphy GP, Chu TM. Quantitation of prostate-
specific antigen in serum by a sensitive enzyme
immunoassay. Cancer Res 1980;40:4658-62.
2.
Lilja H. A kallikrein-like serine protease in
prostatic fluid cleaves the predominant seminal
vesicle protein. J Clin Invest 1985;76:1899-903.
3.
Zhang W-M, Leinonen J, Kalkkinen N, Dowell
B, Stenman U-H. Purification and characteri-
zation of different molecular forms of prostate-
specific antigen in human seminal fluid. Clin
Chem 1995;41:1567-73.
4.
Stenman U-H, Leinonen J, Zhang W-M, Finne
P, Wu P. The clinical importance of free PSA.
Curr Opin Urol 1998;53:53-60.
5.
Oesterling JE, Jacobsen SJ, Klee GG, Pettersson
K, Piironen T, Abrahamsson PA, Stenman UH,
Dowell B, Lövgren T, Lilja H. Free, complexed
and total serum prostate specific antigen: the
establishment of appropriate reference ran-
ges for their concentrations and ratios. J Urol
1995;154:1090-5.
6.
Stenman U-H, Leinonen J, Alfthan H, Rannikko
S, Tuhkanen K, Alfthan O. A complex between
prostate-specific antigen and alpha 1-antichy-
motrypsin is the major form of prostate-specific
antigen in serum of patients with prostatic
cancer: assay of the complex improves clinical
sensitivity for cancer. Cancer Res 1991;51:222-6.
7.
Lilja H, Björk T, Abrahamsson P-A, Sten-
man U-H, Shaw N, Dowell B, et al. Improved
separation between normals, benign prostatic
hyperplasia (BPH) and carcinoma of the pros-
tate (CAP) by measuring freee (F), complexed
(
C) and total concentrations (T) of prostate
specific antigen (PSA). J Urol 1994;151:400A.
8.
Finne P, Auvinen A, Aro J, Juusela H, Määttä-
nen L, Rannikko S, Hakama M, Tammela TL,
Stenman UH. Estimation of prostate cancer risk
on the basis of total and free prostate-specific
antigen, prostate volume and digital rectal exa-
mination. Eur Urol 2002;41:619-27.
9.
Finne P, Auvinen A, Määttänen L, Tammela TL,
Ruutu M, Juusela H, Martikainen P, Hakama M,
Stenman UH. Diagnostic value of free prostate-
specific antigen among men with a prostate-
specific antigen level of <3.0 microg per liter. Eur
Urol. 2008;54:362-70.
10.
Stephan C, Siemβen K, Cammann H, Frieders-
dorff F, Deger S, Schrader M, Miller K, Lein M,
Jung K, Meyer HA. Between-method differences
in prostate-specific antigen assays affect pros-
tate cancer risk prediction by nomograms. Clin
Chem. 2011 May 24. [Epub ahead of print].
11.
Stenman U-H, Hakama M, Knekt P, Aromaa A,
Teppo L, Leinonen J. Serum concentrations of
prostate specific antigen and its complex with
a
1
-
antichymotrypsin before diagnosis of prostate
cancer. Lancet 1994;344:1594-8.
12.
Bill-Axelson A, Holmberg L, Ruutu M, Garmo
H, Stark JR, Busch C, et al. Radical prostatectomy
versus watchful waiting in early prostate cancer.
N Engl J Med 2011;364:1708-17.
13.
Visapää H, Hotakainen K, Lundin J, Ala-Opas M,
Stenman UH. The proportion of free PSA and
upgrading of biopsy gleason score after radical
prostatectomy. Urol Int 2010;84:378-81.
14.
Finne P, Finne R, Bangma C, Hugosson J,
Hakama M, Auvinen A, Stenman UH. Algo-
rithms based on prostate-specific antigen (PSA),
free PSA, digital rectal examination and prostate
volume reduce false-positive PSA results in pros-
tate cancer screening. Int J Cancer 2004;111:310-
5.
15.
Roobol MJ, Kerkhof M, Schroder FH, Cuzick J,
Sasieni P, Hakama M, et al. Prostate Cancer Mor-
tality Reduction by Prostate-Specific Antigen-
Based Screening Adjusted for Nonattendance
and Contamination in the European Rando-
mised Study of Screening for Prostate Cancer
(
ERSPC). Eur Urol 2009.
16.
Hugosson J, Carlsson S, Aus G, Bergdahl S, Kha-
tami A, Lodding P, et al. Mortality results from
the Goteborg randomised population-based
prostate-cancer screening trial. Lancet Oncol
2010;11:725-32.
17.
Roobol MJ, Carlsson S, Hugosson J. Meta-
analysis finds screening for prostate cancer with
PSA does not reduce prostate cancer-related
or all-cause mortality but results likely due to
heterogeneity - the two highest quality studies
identified do find prostate cancer-related mor-
tality reductions. Evid Based Med 2011;16:20-1.
